Po Zhao1, Wu Liu, Ya-Li Lu. 1. Department of Pathology, Chinese People's Liberation Army General Hospital, Beijing 100853, China. zhaopo@plagh.com.cn
Abstract
AIM: To investigate the expression of fragile histidine triad (FHIT) protein, and the possible relationship between FHIT expression and clinicopathological indices in gastric carcinoma. METHODS: FHIT protein expression was examined in 76 cases of gastric carcinoma, 58 cases of intraepithelial neoplasia, and 76 cases of corresponding normal mucosae by immunohistochemical method to analyze its relationship to histological grade, clinical stage, metastatic status and prognosis. RESULTS: The FHIT protein expression was positive in 28/76 (36.8%) cases of adenocarcinoma tissue, 22/58 (37.9%) cases of adjacent dysplastic tissue and 76/76 (100%) cases of distal normal gastric mucosa. There was a significant difference in the expression of FHIT protein between cancer or adjacent intraepithelial neoplasia and normal gastric mucosa (P = 0.000). FHIT protein expression was found in 64.3% (18/28) of grades I and II cancers, and 20.8% (10/48) of grade III cancers (P = 0.000), in 56.3% (18/32) of stages I and II cancers and 22.7% (10/44) of stages III and IV cancers (P = 0.004), and in 63.6% (14/22) of cancers without metastasis but only 25.9% (14/54) of those with metastasis (P = 0.003). The significant difference in the expression of FHIT was found between histological grade, clinical stage and metastatic status of cancer. Follow-up data showed that there was a significant difference in median survival time between cancer patients with expression of FHIT (71 mo) and those without (33 mo, log rank = 20.78, P = 0.000). CONCLUSION: FHIT protein is an important tumor suppressor protein. Loss of FHIT protein expression may be associated with carcinogenesis, invasion, metastasis and prognosis of gastric adenocarcinoma.
AIM: To investigate the expression of fragile histidine triad (FHIT) protein, and the possible relationship between FHIT expression and clinicopathological indices in gastric carcinoma. METHODS:FHIT protein expression was examined in 76 cases of gastric carcinoma, 58 cases of intraepithelial neoplasia, and 76 cases of corresponding normal mucosae by immunohistochemical method to analyze its relationship to histological grade, clinical stage, metastatic status and prognosis. RESULTS: The FHIT protein expression was positive in 28/76 (36.8%) cases of adenocarcinoma tissue, 22/58 (37.9%) cases of adjacent dysplastic tissue and 76/76 (100%) cases of distal normal gastric mucosa. There was a significant difference in the expression of FHIT protein between cancer or adjacent intraepithelial neoplasia and normal gastric mucosa (P = 0.000). FHIT protein expression was found in 64.3% (18/28) of grades I and II cancers, and 20.8% (10/48) of grade III cancers (P = 0.000), in 56.3% (18/32) of stages I and II cancers and 22.7% (10/44) of stages III and IV cancers (P = 0.004), and in 63.6% (14/22) of cancers without metastasis but only 25.9% (14/54) of those with metastasis (P = 0.003). The significant difference in the expression of FHIT was found between histological grade, clinical stage and metastatic status of cancer. Follow-up data showed that there was a significant difference in median survival time between cancerpatients with expression of FHIT (71 mo) and those without (33 mo, log rank = 20.78, P = 0.000). CONCLUSION:FHIT protein is an important tumor suppressor protein. Loss of FHIT protein expression may be associated with carcinogenesis, invasion, metastasis and prognosis of gastric adenocarcinoma.
Authors: S H Lee; W H Kim; H K Kim; K M Woo; H S Nam; H S Kim; J G Kim; M H Cho Journal: Biochem Biophys Res Commun Date: 2001-06-15 Impact factor: 3.575
Authors: Alba Rocco; Laslo Schandl; Jie Chen; Hongbing Wang; Zsolt Tulassay; Deirdre McNamara; Peter Malfertheiner; Matthias P A Ebert Journal: J Cancer Res Clin Oncol Date: 2003-03-04 Impact factor: 4.553
Authors: D L Greenspan; D C Connolly; R Wu; R Y Lei; J T Vogelstein; Y T Kim; J E Mok; N Muñoz; F X Bosch; K Shah; K R Cho Journal: Cancer Res Date: 1997-11-01 Impact factor: 12.701
Authors: G Sozzi; U Pastorino; L Moiraghi; E Tagliabue; F Pezzella; C Ghirelli; S Tornielli; L Sard; K Huebner; M A Pierotti; C M Croce; S Pilotti Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: David Velázquez-Fernández; Cecilia Laurell; Milena Saqui-Salces; Juan Pablo Pantoja; Fernando Candanedo-Gonzalez; Alfredo Reza-Albarrán; Armando Gamboa-Dominguez; Miguel F Herrera Journal: World J Surg Date: 2006-05 Impact factor: 3.352
Authors: Stefania Nobili; Lorenzo Bruno; Ida Landini; Cristina Napoli; Paolo Bechi; Francesco Tonelli; Carlos A Rubio; Enrico Mini; Gabriella Nesi Journal: World J Gastroenterol Date: 2011-01-21 Impact factor: 5.742
Authors: Roberto Cirombella; Giuseppe Montrone; Antonella Stoppacciaro; Simona Giglio; Stefano Volinia; Paolo Graziano; Kay Huebner; Andrea Vecchione Journal: Cancer Lett Date: 2010-05-28 Impact factor: 8.679